Sandison, Taylor

Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial

Thompson, G. R., Soriano, A., Cornely, O. A., Kullberg, B. J., Kollef, M., Vazquez, J., Honore, P. M., Bassetti, M., Pullman, J., Chayakulkeeree, M., et al. (2023) · The Lancet

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 192

Rezafungin versus caspofungin in a phase 2, randomized, double-blind study for the treatment of candidemia and invasive candidiasis: the STRIVE Trial

Thompson, G. R., Soriano, A., Skoutelis, A., Vazquez, J. A., Honore, P. M., Horcajada, J. P., Spapen, H., Bassetti, M., Ostrosky-Zeichner, L., Das, A. F., et al. (2021) · Clinical Infectious Diseases

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 163

Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults

Sandison, T., Ong, V., Lee, J., & Thye, D. (2017) · Antimicrobial Agents and Chemotherapy

Antifungal resistance and susceptibilityAntibiotics Pharmacokinetics and Efficacy

Cited by 161

1718. Rezafungin Clinical Safety and Efficacy in Patients With Candidemia and/or Invasive Candidiasis in the Randomized, Double-Blind, Multicenter, Phase 2 STRIVE Study

Thompson, G. R., Vazquez, J., Soriano, A., Skoutelis, A., Ostrosky-Zeichner, L., Mena, K., Navalta, L., Sandison, T., & Pappas, P. (2018) · Open Forum Infectious Diseases

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 5

982. Effect of hepatic impairment on the safety and pharmacokinetics of rezafungin

Huguet, J., Ong, V., Sandison, T., Melara, R. M., Marbury, T. C., Jandourek, A., & Flanagan, S. (2021) · Open Forum Infectious Diseases

Antifungal resistance and susceptibilityAntibiotics Pharmacokinetics and Efficacy

Cited by 4